Results 71 to 80 of about 8,834,434 (252)

Study flow diagram.

, 2022
OAT, opioid agonist treatment; OATS, Opioid Agonist Treatment Safety.
Duncan Webster (1476118), Dan Lewer (8452326), Thomas D. Brothers (11524501), Andrew Hayward (101478), Louisa Degenhardt (20846), Samantha Colledge-Frisby (13118989), Michael Farrell (164574), Nicola Jones (237315), Matthew Hickman (83053)   +8 more
core   +1 more source

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

International Journal of Cancer, EarlyView.
ABSTRACT Medication taken for other reasons than for the treatment of malignant disease, termed concomitant medication, is known to affect outcomes when used with immune checkpoint inhibitor therapy and other oncological drugs. However, no research in humans has addressed the relationship between concomitant medications and efficacy of oncolytic ...
Santeri A. Pakola, Tatiana V. Kudling, Nea Ojala, James H. A. Clubb, Victor Arias, Elise Jirovec, Mirte van der Heijden, Arianna Eleuteri, Lyna Haybout, Susanna Grönberg‐Vähä‐Koskela, Katriina Jalkanen, Tuomo Alanko, Matthew S. Block, Inge Marie Svane, Anna Kanerva, Otto Hemminki, Dafne C. A. Quixabeira, Claudia Kistler, Suvi Sorsa, Victor Cervera‐Carrascon, Akseli Hemminki   +20 more
wiley   +1 more source

Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17.

PLoS ONE, 2019
BACKGROUND:Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist ...
Justin C Yang, Andres Roman-Urrestarazu, Carol Brayne   +2 more
doaj   +1 more source

Opioid agonist treatment for pharmaceutical opioid dependent people (Protocol)

, 2014
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of maintenance agonist pharmacotherapy treatments for the treatment of pharmaceutical opioid ...
Linda Gowing (20229114), Suzanne Nielsen (9618626), Briony Larance (19587904), Nicholas Lintzeris (5237414), Louisa Degenhardt (20846), Chyanne Kehler (20229117)   +5 more
core  

Addressing in‐hospital substance use: A bioethical evaluation of two possible approaches

Journal of Hospital Medicine, EarlyView.
Abstract Up to 40% of patients with substance use disorder report using non‐prescribed drugs when hospitalized. In‐hospital substance (IHSU) use is associated with poor outcomes and raises safety concerns for healthcare providers. Despite its prevalence, little guidance exists regarding best practices in responding to IHSU.
John C. Messinger, Taylor Baisey, Johanna Sluser, Benjamin A. Barsky, Marlene Martin, Leslie W. Suen   +5 more
wiley   +1 more source

Regulation of dynorphin gene expression by kappa-opioid agonist treatment

, 2002
The effects of K-opioid agonist treatment on prodynorphin mRNA expression in the rat brain were studied. Rats were treated with the selective kappa-opioid agonist U-69593 or vehicle for 5 days and prodynorphin mRNA was measured on day 8 (3 days after the
IZENWASSER S., COLLINS S, ROMUALDI P, CANDELETTI S, D'ADDARIO, Claudio   +4 more
core   +1 more source

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)

Substance Abuse Treatment, Prevention, and Policy
Background Across different types of oral Opioid Agonist Treatment for people with Opioid Use Disorder, receiving a dose that meets their needs is associated with better outcomes. Evidence also shows patients are more likely to receive an “adequate dose”
Scott Beaumont, Tianna Magel, Scott MacDonald, Scott Harrison, Martin Schechter, Eugenia Oviedo-Joekes   +5 more
doaj   +1 more source

Fentanyl exposure among patients seeking opioid treatment

, 2018
Aim: Overdoses attributed to the potent opioid agonist fentanyl have substantially increased in recent years. Despite these serious public health consequences, many opioid treatment providers do not currently include a fentanyl assay in their urine ...
Ochalek, T A, Sigmon, S C, Higgins, S T, Parker, Maria Anne   +3 more
core   +1 more source

Chronic Kidney Disease‐Associated Pruritus Is Linked to Selective Enrichment of Taurine‐Conjugated Bile Acid Subspecies

JEADV Clinical Practice, EarlyView.
Chronic kidney disease‐associated pruritus (CKDaP) is a frequent complication of advanced CKD with an incompletely understood pathophysiology. We identified a significantly altered glycine‐to‐taurine conjugated bile acid ratio in patients with CKDaP despite unchanged total serum bile acid concentrations.
Miriam M. Düll, Manfred Rauh, Peter Dietrich, Marcel Vetter, Jonas Schmid, Thomas Mettang, Andreas E. Kremer   +6 more
wiley   +1 more source

The journey of opioid substitution therapy in India: Achievements and challenges

Indian Journal of Psychiatry, 2017
Opioids are one of the most problematic illegal substances globally. Opioid abuse is associated with complications in various spheres of the user's life, his/her family, and the society.
Ravindra Rao
doaj   +1 more source